Difluprednate: Difference between revisions

{{Short description|Corticosteroid drug}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 405835759

| image2 = Difluprednate 3D.png

| width2 = 150

<!--Clinical data-->

| tradename = Durezol

| Drugs.com = {{drugs.com|monograph|difluprednate}}

| MedlinePlus = a609025

| licence_US = Difluprednate

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->

| legal_UK = <!-- GSL / P / POM / CD -->

| legal_US = Rx-only

| legal_US_comment = <ref name="Durezol FDA label">{{cite web | title=Durezol emulsion | website=DailyMed | date=11 July 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d07b65d5-f8e3-4594-a7fb-108218746cec | access-date=7 March 2023}}</ref>

| legal_status =

| routes_of_administration = [[Ophthalmic drug administration|Eye drops]]

<!--Pharmacokinetic data-->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!--Identifiers-->

| CAS_number_Ref = {{cascite|correct|??}}

| ATC_supplemental = {{ATC|S01|BA16}}

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB06781

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 391990

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = S8A06QG2QE

| KEGG_Ref = {{keggcite|correct|kegg}}

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201749

| ChEBI_Ref =

| ChEBI = 31485

<!--Chemical data-->

| IUPAC_name = [(6''S'',8''S'',9''R'',10''S'',11''S'',13''S'',14''S'',17''R'')-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[''a'']phenanthren-17-yl] butanoate

| C=27 | H=34 | F=2 | O=7

| SMILES = [H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

| StdInChI = 1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1

| StdInChIKey = WYQPLTPSGFELIB-JTQPXKBDSA-N

'''Difluprednate''', sold under the brand name '''Durezol''', is a [[corticosteroid]] used for the treatment of post-operative ocular inflammation and pain.<ref name="Durezol FDA label" />

It was approved for medical use in the United States in June 2008.<ref name="Durezol FDA label" /><ref>{{cite web | title=Drug Approval Package: Durezol (Difluprednate) NDA #022212 | website=U.S. [[Food and Drug Administration]] (FDA) | date=25 July 2008 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000TOC.cfm | access-date=7 March 2023}}</ref><ref>{{cite press release

| url = https://www.drugs.com/newdrugs/sirion-therapeutics-announces-fda-approval-durezol-postoperative-ocular-inflammation-pain-1031.html

| access-date = 2008-06-30

}}</ref> It is available as a [[generic medication]].<ref>{{cite web | title=Competitive Generic Therapy Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2023 | url=https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | access-date=29 June 2023 | archive-date=29 June 2023 | archive-url=https://web.archive.org/web/20230629233651/https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | url-status=live }}</ref>

== Medical uses ==

Difluprednate is [[indicated]] for the treatment of inflammation and pain associated with ocular surgery; and the treatment of endogenous anterior uveitis.<ref name="Durezol FDA label" />

==Clinical trials==

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior [[uveitis]]<ref>{{ClinicalTrialsGov|NCT00501579|Study of Difluprednate in the Treatment of Uveitis}}</ref><ref name="Sheppard_2014">{{cite journal | vauthors = Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS | title = Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study | journal = Investigative Ophthalmology & Visual Science | volume = 55 | issue = 5 | pages = 2993–3002 | date = May 2014 | pmid = 24677110 | pmc = 4581692 | doi = 10.1167/iovs.13-12660 }}</ref>

{{Glucocorticoids}}

{{Glucocorticoidics}}

[[Category:Corticosteroid esters]]

[[Category:Butyrate esters]]

[[Category:Drugs developed by Novartis]]

[[Category:Corticosteroids]]

{{dermatologic-drug-stub}}